This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

MediciNova Reports Third Quarter 2013 Results

SAN DIEGO, Nov. 7, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:4875), today announced financial results for the third quarter ended September 30, 2013.

A detailed discussion of financial results and product development programs can be found in MediciNova's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, which was filed with the Securities and Exchange Commission on November 7, 2013 and is available through investors.medicinova.com/sec.cfm.

Financial Results

For the quarter ended September 30, 2013, MediciNova reported a net loss of $2.2 million, or $0.10 per share compared to a net loss of $2.4 million, or $0.14 per share for the same period last year. The Company reported no service revenue for the quarter ended September 30, 2013, whereas the Company recorded revenue relating to services performed under an agreement with Kissei Pharmaceutical Co., Ltd. of $0.1 million for the quarter ended September 30, 2012. Research and development expenses were $0.8 million for the quarter ended September 30, 2013, as compared to $0.9 million for the quarter ended September 30, 2012. General and administrative expenses were $1.5 million for the quarter ended September 30, 2013, as compared to $1.6 million for the quarter ended September 30, 2012. The decreases in research and development and general and administrative expenses were due primarily to reductions in employee-related expenses.

At September 30, 2013, MediciNova had available cash and cash equivalents of $10.7 million and working capital of $9.9 million. Between August 21, 2012, the date of the Common Stock Purchase Agreement with Aspire Capital Fund, LLC, or Aspire, and September 30, 2013, the Company generated net proceeds of $5.4 million under the Aspire agreement.  Between April 17, 2013, the date of the at-the-market Equity Distribution Agreement with Macquarie Capital (USA) Inc., or MCUSA, and September 30, 2013, the Company generated net proceeds of $5.6 million under the MCUSA agreement. In May, the Company generated net proceeds of $3.7 million under a Securities Purchase Agreement with certain accredited investors. The Company has not generated additional proceeds under the above agreements subsequent to September 30, 2013 through today's date. On October 16, 2103 the Company entered into a new Equity Distribution Agreement with MCUSA and the Company has not generated material proceeds under the new MCUSA agreement between that date and November 5, 2013.

Stock quotes in this article: MNOV 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs